Literature DB >> 10225963

Finally, CTLA4Ig graduates to the clinic.

M H Sayegh1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10225963      PMCID： PMC408363          DOI： 10.1172/JCI6952

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  28 in total

1.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

2.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.

Authors:  E R Kearney; T L Walunas; R W Karr; P A Morton; D Y Loh; J A Bluestone; M K Jenkins
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

3.  CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system.

Authors:  S J Khoury; E Akalin; A Chandraker; L A Turka; P S Linsley; M H Sayegh; W W Hancock
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

4.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.

Authors:  C P Larsen; E T Elwood; D Z Alexander; S C Ritchie; R Hendrix; C Tucker-Burden; H R Cho; A Aruffo; D Hollenbaugh; P S Linsley; K J Winn; T C Pearson
Journal:  Nature       Date:  1996-05-30       Impact factor: 49.962

5.  IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways.

Authors:  B T Konieczny; Z Dai; E T Elwood; S Saleem; P S Linsley; F K Baddoura; C P Larsen; T C Pearson; F G Lakkis
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

Review 6.  Signals and signs for lymphocyte responses.

Authors:  C A Janeway; K Bottomly
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

7.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

8.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

9.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

10.  CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2.

Authors:  M H Sayegh; E Akalin; W W Hancock; M E Russell; C B Carpenter; P S Linsley; L A Turka
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307
View more
  13 in total

1.  CD28-independent induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; K A Abdallah; V Dong; H Yagita; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Science, medicine, and the future: Tolerance and autoimmunity.

Authors:  I R Mackay
Journal:  BMJ       Date:  2000-07-08

Review 3.  Challenges to achieving clinical transplantation tolerance.

Authors:  A D Salama; G Remuzzi; W E Harmon; M H Sayegh
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

4.  New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.

Authors:  Masayuki Sho; Sigrid E Sandner; Nader Najafian; Alan D Salama; Victor Dong; Akira Yamada; Koji Kishimoto; Hiroshi Harada; Isabela Schmitt; Mohamed H Sayegh
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

5.  CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.

Authors:  Susanne Roser-Page; Tatyana Vikulina; Majd Zayzafoon; M Neale Weitzmann
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

6.  Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma.

Authors:  C K Wong; S W M Lun; F W S Ko; W K Ip; D S C Hui; C W K Lam
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

7.  CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin.

Authors:  Susanne Roser-Page; Tatyana Vikulina; Daiana Weiss; Mark M Habib; George R Beck; Roberto Pacifici; Timothy F Lane; M Neale Weitzmann
Journal:  Ann N Y Acad Sci       Date:  2018-03-03       Impact factor: 5.691

Review 8.  Bone and the Immune System.

Authors:  M Neale Weitzmann
Journal:  Toxicol Pathol       Date:  2017-10-18       Impact factor: 1.902

9.  CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.

Authors:  M Mihara; I Tan; Y Chuzhin; B Reddy; L Budhai; A Holzer; Y Gu; A Davidson
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 10.  Psoriasis and the new biologic agents: interrupting a T-AP dance.

Authors:  Scott R A Walsh; Neil H Shear
Journal:  CMAJ       Date:  2004-06-22       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.